NTRBW
Nutriband Inc. [NTRBW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NTRBW Stock Summary
Top 10 Correlated ETFs
NTRBW
Top 10 Correlated Stocks
NTRBW
In the News
NTRBW Financial details
Company Rating
-
Market Cap
20.49M
Income
-5.27M
Revenue
2.09M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
30 Apr 2023
P/E
-4.28
Forward P/E
-
PEG
1.16
P/S
10.8
P/B
3.95
P/C
-
P/FCF
-6.2
Quick Ratio
2
Current Ratio
2.79
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.67
EPS next Y
-
EPS next Q
-
EPS this Y
-46.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.47%
Revenue last 5Y
53.34%
Revenue Q/Q
-34.77%
EPS Q/Q
100%
-
-
-
-
SMA20
-46.22%
SMA50
-35.68%
SMA100
-15.79%
Inst Own
-
Inst Trans
-
ROA
-62%
ROE
-73%
ROC
-0.63%
Gross Margin
39%
Oper. Margin
-236%
Profit Margin
-252%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.189-3.76
52W High
-
52W Low
-
RSI
40.78
Rel Volume
0.01
Avg Volume
10.21K
Volume
136
Perf Week
14.53%
Perf Month
-54.27%
Perf Quarter
-0.74%
Perf Half Y
16.52%
-
-
-
-
Beta
0.44
-
-
Volatility
0.03%, 0.53%
Prev Close
4.69%
Price
1.34
Change
4.69%
Company Profile
- Volume Average 10.21K
- Market Capitalization 20.49M
- Employee 3
- CEO Mr. Gareth Sheridan
- Headquarters Orlando,FL,US
- IPO Date 2021-10-01
-
Website
http://nutriband.com 
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
